2 Cannabis Stocks That Are Quietly Trouncing the Market in 2026

Trulieve and Cronos have each gained roughly 27% in 2026 through Sept. 18, outperforming the S&P 500's 12% rise, supported by improving operating fundamentals rather than solely speculative momentum. Trulieve reported Q2 revenue of $271 million, 60% gross margin, $98 million of adjusted EBITDA and $74 million in first-half free cash flow, while Cronos posted record Q2 revenue of $53 million, up 58% year over year, with gross margin expanding to 54% from 43%. Trulieve's NYSE listing and $325 million cash balance, alongside Cronos' $827 million liquidity and 12.3 million shares repurchased, strengthen their investment cases, though cannabis regulation, pricing pressure and potential Israeli import restrictions remain material risks.

Analysis

The investable distinction is cash conversion versus reported growth. TRLV's ability to sustain free cash flow following its corporate restructuring would justify a re-rating toward other cash-generative consumer/healthcare small caps, but the key diligence item is whether cash generation reflects durable working-capital discipline rather than deferred payables, inventory liquidation, or reduced growth capex. NYSE access can tighten the liquidity discount over the next 1-3 months, yet it does not eliminate the federal-policy and banking constraints that still limit the natural institutional owner base.

CRON's operating leverage is improving, but its valuation support is likely increasingly balance-sheet-driven: its financial assets create a downside buffer while buybacks reduce the share count against a relatively small operating base. The less obvious risk is that international growth concentration converts a regulatory action in Israel into both a revenue and multiple event; even a modest tariff could force price concessions, impair margins, and undermine the market's diversification narrative. Germany is strategically more valuable than Israel because it offers a larger long-duration medical channel, but meaningful contribution will take quarters rather than weeks.

Consensus may be over-attributing both rallies to fundamental normalization. Cannabis equities remain highly sensitive to regulatory headlines and retail flows, so the next 1-3 month upside requires confirmation in reported margins and cash flow, not merely continued favorable sentiment. Prefer TRLV for evidence-based execution; treat CRON as a cash-backed growth optionality position, with upside contingent on international revenue becoming less concentrated.

Key Decisions for Investors

• Initiate a modest long TRLV position only after the next earnings release confirms positive quarterly free cash flow and stable gross margin; target a 6-12 month re-rating on liquidity and cash-generation durability. Exit if operating cash flow turns negative for two consecutive quarters or EBITDA margin falls below 30%.
• Use a pair trade: long TRLV / short MSOS over 3-6 months. TRLV has a clearer company-specific cash-flow catalyst, while MSOS retains broader exposure to policy disappointment and weaker U.S. operators; reassess if federal reform advances materially enough to lift all MSOs indiscriminately.
• Maintain CRON as a watch-list long rather than chase after the rally. Enter on a pullback or after confirmation that Israel growth persists without pricing concessions and German sales accelerate; downside protection should be assessed against net cash per share, while a new Israeli import restriction is the thesis breaker.
• Monitor CRON's quarterly buyback pace, cash deployment, and international revenue mix. A slowdown in repurchases alongside rising operating losses would signal that the apparent balance-sheet floor is being consumed rather than accretively deployed.